Indications and uses
Metronidazole topical cream is indicated for topical application in the treatment of inflammatory papules and pustules of rosacea.
Metronidazole topical cream is indicated for topical application in the treatment of inflammatory papules and pustules of rosacea.
Apply and rub in a thin layer of metronidazole topical cream twice daily, morning and evening, to entire affected areas after washing. Areas to be treated should be washed with a mild cleanser before application. Patients may use cosmetics after application of metronidazole topical cream.
Metronidazole topical cream contains metronidazole, USP, at a concentration of 7.5 mg per gram (0.75%) in an emollient cream consisting of benzyl alcohol, emulsifying wax, glycerin, isopropyl palmitate, purified water, sorbitol solution, lactic acid and sodium hydroxide to adjust pH.
Metronidazole is a member of the imidazole class of antibacterial agents and is classified therapeutically as an antiprotozoal and anti-bacterial agent. Chemically, metronidazole is 2-methyl-5-nitro-1H-imidazole-1-ethanol. The molecular formula is C6H9N3O3 and molecular weight is 171.15.
Metronidazole is represented by the following structural formula:

The mechanisms by which metronidazole acts in the treatment of rosacea are unknown, but appear to include an anti-inflammatory effect.
Metronidazole topical cream is indicated for topical application in the treatment of inflammatory papules and pustules of rosacea.
Metronidazole topical cream is contraindicated in individuals with a history of hypersensitivity to metronidazole, or other ingredients of the formulation.
Topical metronidazole has been reported to cause tearing of the eyes. Therefore, contact with the eyes should be avoided. If a reaction suggesting local irritation occurs, patients should be directed to use the medication less frequently or discontinue use. Metronidazole is a nitroimidazole and should be used with care in patients with evidence of, or history of blood dyscrasia.
This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.
Oral metronidazole has been reported to potentiate the anticoagulant effect of warfarin and coumarin anticoagulants, resulting in a prolongation of prothrombin time. The effect of topical metronidazole on prothrombin time is not known.
Metronidazole has shown evidence of carcinogenic activity in a number of studies involving chronic, oral administration in mice and rats but not in studies involving hamsters.
Metronidazole has shown evidence of mutagenic activity in several in vitro bacterial assay systems. In addition, a dose-response increase in the frequency of micronuclei was observed in mice after intraperitoneal injections and an increase in chromosome aberrations have been reported in patients with Crohn's disease who were treated with 200 mg/day to 1,200 mg/day of metronidazole for 1 months to 24 months.
However, no excess chromosomal aberrations in circulating human lymphocytes have been observed in patients treated for 8 months.
Teratogenic effects
There are no adequate and well-controlled studies with the use of metronidazole topical cream in pregnant women. Metronidazole crosses the placental barrier and enters the fetal circulation rapidly. No fetotoxicity was observed after oral metronidazole in rats or mice. However, because animal reproduction studies are not always predictive of human response and since oral metronidazole has been shown to be a carcinogen in some rodents, this drug should be used during pregnancy only if clearly needed.
After oral administration, metronidazole is secreted in breast milk in concentrations similar to those found in the plasma. Even though blood levels are significantly lower with topically applied metronidazole than those achieved after oral administration of metronidazole, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Safety and effectiveness in pediatric patients have not been established.
In controlled clinical trials, the total incidence of adverse reactions associated with the use of metronidazole topical cream was approximately 10%. Skin discomfort (burning and stinging) was the most frequently reported event followed by erythema, skin irritation, pruritus and worsening of rosacea.
All individual events occurred in less than 3% of patients. The following additional adverse experiences have been reported with the topical use of metronidazole: dryness, transient redness, metallic taste, tingling or numbness of extremities and nausea.
To report SUSPECTED ADVERSE REACTIONS, contact Viona Pharmaceuticals Inc. at 1-888-304-5011 or FDA at 1-800-FDA-1088 or
www.fda.gov/medwatch.
Apply and rub in a thin layer of metronidazole topical cream twice daily, morning and evening, to entire affected areas after washing.
Areas to be treated should be washed with a mild cleanser before application. Patients may use cosmetics after application of metronidazole topical cream.
Metronidazole topical cream, 0.75% is white to off-white homogeneous cream, free from lumps, free from gritty particles and foreign matter without phase separation and is supplied as follows:
45 gram aluminum tube | NDC 68788-8552-4 |
Storage conditions: Store at 20°C to 25°C (68ºF to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature].
Call your doctor for medical advice about side effects. You may report side effects to Viona Pharmaceuticals Inc. at 1-888-304-5011 or FDA at 1-800-FDA-1088.
Manufactured by:
Zydus Lifesciences Ltd.
Changodar, Ahmedabad, India
Distributed by:
Viona Pharmaceuticals Inc.
Cranford, NJ 07016
Rev.: 01/23
Relabeled By: Preferred Pharmaceuticals Inc.
| Resource | Code type | Value | Equivalent identifiers | Source image |
|---|---|---|---|---|
| Data code | Code 128 | 1497 | 3d32ce01-d498-47d9-b589-3b2b8c741524-02.jpg | |
| Data code | QR Code | 1497 | 3d32ce01-d498-47d9-b589-3b2b8c741524-02.jpg |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 8ffb9b1d-3ed7-ba2e-677e-47d4d134fd55 | Product name | 5 | 20251024 |
| 7f6d14e0-4366-41bc-a4a9-b74c79a20e17 | Product name | 1 | 20250623 |
| e6d321b0-0e5e-7da6-f043-92b6a91f00a1 | Product name | 5 | 20250515 |
| e1aac33b-94ae-4ee9-905b-299f7263853b | Product name | 3 | 20250124 |
| 16642716-d28a-4f90-8dcb-3921cd8c8109 | Product name | 4 | 20240516 |
| 0be8e4ae-4d57-49f3-b3a9-e4728b4e8d15 | Product name | 1 | 20240313 |
| dea2eded-d1e7-46bb-9a3d-f8dc20de6277 | Product name | 1 | 20190408 |
| a5070875-62bb-61e1-fd46-8f7054197a40 | Product name | 8 | 20180215 |
| 0add4de9-d152-3375-3390-1123dddc5e3d | Product name | 1 | 20140508 |
| 33ca0fcc-1011-92dc-50a9-a383683eed1e | Product name | 1 | 20140508 |
| 53f39d9f-cd3f-04e1-c668-d4580719d57d | Product name | 1 | 20140508 |
| a804000f-b74f-0b5d-d17b-aa767c286ddb | Product name | 1 | 20140508 |
| a91ea265-6e02-c08f-93c8-686d54180529 | Product name | 1 | 20140508 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 68788-8552-4 | GM - Gram | 68788-8552 | 9433a944-27a5-417a-9d36-deb50ee7594c | 1 | 2024-01-04 |
| 72578-129-08 | GM - Gram | 72578-129 | 7db5feda-08ab-4fef-b930-07d9640d8152 | 1 | 2023-09-05 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 68788-8552 | 68788-8552-4 |
| 72578-129 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| METRONIDAZOLE | 140QMO216E | ACTIB |
| BENZYL ALCOHOL | LKG8494WBH | IACT |
| GLYCERIN | PDC6A3C0OX | IACT |
| ISOPROPYL PALMITATE | 8CRQ2TH63M | IACT |
| LACTIC ACID, UNSPECIFIED FORM | 33X04XA5AT | IACT |
| SODIUM HYDROXIDE | 55X04QC32I | IACT |
| SORBITOL SOLUTION | 8KW3E207O2 | IACT |
| WATER | 059QF0KO0R | IACT |
| Version | Effective date | Source | Hydrated |
|---|---|---|---|
| 2 | 2025-01-15 | full-release | 2026-05-31 21:22:58 |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A217128-001 | METRONIDAZOLE | METRONIDAZOLE | 0.75% | CREAM / TOPICAL | BX | 2023-04-21 |
| Application-product | TE code |
|---|---|
| A217128-001 | BX |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A217128-001 | METRONIDAZOLE | 0.75% | CREAM / TOPICAL | BX | 2023-04-21 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A217128-001 | METRONIDAZOLE | 0.75% | CREAM / TOPICAL | BX | 2023-04-21 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | A217128-001 | METRONIDAZOLE | 0.75% | CREAM / TOPICAL | BX | 2023-04-21 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A217128-001 | METRONIDAZOLE | 0.75% | CREAM / TOPICAL | BX | 2023-04-21 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | A217128-001 | METRONIDAZOLE | 0.75% | CREAM / TOPICAL | BX | 2023-04-21 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A217128-001 | METRONIDAZOLE | 0.75% | CREAM / TOPICAL | AB | 2023-04-21 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A217128-001 | METRONIDAZOLE | 0.75% | CREAM / TOPICAL | AB | 2023-04-21 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A217128-001 | METRONIDAZOLE | 0.75% | CREAM / TOPICAL | AB | 2023-04-21 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A217128-001 | METRONIDAZOLE | 0.75% | CREAM / TOPICAL | AB | 2023-04-21 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A217128-001 | METRONIDAZOLE | 0.75% | CREAM / TOPICAL | AB | 2023-04-21 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A217128-001 | METRONIDAZOLE | 0.75% | CREAM / TOPICAL | AB | 2023-04-21 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | A217128-001 | METRONIDAZOLE | 0.75% | CREAM / TOPICAL | AB | 2023-04-21 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A217128-001 | METRONIDAZOLE | 0.75% | CREAM / TOPICAL | AB | 2023-04-21 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A217128-001 | METRONIDAZOLE | 0.75% | CREAM / TOPICAL | AB | 2023-04-21 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A217128-001 | METRONIDAZOLE | 0.75% | CREAM / TOPICAL | AB | 2023-04-21 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | A217128-001 | METRONIDAZOLE | 0.75% | CREAM / TOPICAL | AB | 2023-04-21 | 8072bd15b7f6… | |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A217128-001 | METRONIDAZOLE | 0.75% | CREAM / TOPICAL | AB | 2023-04-21 | 6a51e52b5d6a… | |
| 2024-02-18 07:12 UTC | 2024-02 | A217128-001 | METRONIDAZOLE | 0.75% | CREAM / TOPICAL | AB | 2023-04-21 | 1c564ffb4f44… | |
| 2023-12-20 04:57 UTC | 2023-12 | A217128-001 | METRONIDAZOLE | 0.75% | CREAM / TOPICAL | AB | 2023-04-21 | ea1830bbd6c7… | |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A217128-001 | METRONIDAZOLE | 0.75% | CREAM / TOPICAL | AB | 2023-04-21 | a72a2bbeb626… | |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A217128-001 | METRONIDAZOLE | 0.75% | CREAM / TOPICAL | AB | 2023-04-21 | 9b2671bbb829… | |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A217128-001 | METRONIDAZOLE | 0.75% | CREAM / TOPICAL | AB | 2023-04-21 | a67488948f0b… | |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A217128-001 | METRONIDAZOLE | 0.75% | CREAM / TOPICAL | AB | 2023-04-21 | 3f0d92c62455… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A217128-001 | METRONIDAZOLE | 0.75% | CREAM / TOPICAL | BX | 2023-04-21 | a50c72e98297… |
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A217128-001 | BX | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A217128-001 | BX | 1 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | A217128-001 | BX | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A217128-001 | BX | 1 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | A217128-001 | BX | 1 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A217128-001 | AB | 1 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A217128-001 | AB | 1 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A217128-001 | AB | 1 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A217128-001 | AB | 1 | 2680178bc6a6… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A217128-001 | AB | 1 | 5bbf6a4d5a75… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A217128-001 | AB | 1 | d8e5a09893c0… |
| 2024-10-29 15:01 UTC | 2024-10 | A217128-001 | AB | 1 | d06236e962d9… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A217128-001 | AB | 1 | 79d66fd596c7… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A217128-001 | AB | 1 | 301d65b070ca… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A217128-001 | AB | 1 | 1e350fbaab3a… |
| 2024-05-31 18:47 UTC | 2024-05 | A217128-001 | AB | 1 | 8072bd15b7f6… |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A217128-001 | AB | 1 | 6a51e52b5d6a… |
| 2024-02-18 07:12 UTC | 2024-02 | A217128-001 | AB | 1 | 1c564ffb4f44… |
| 2023-12-20 04:57 UTC | 2023-12 | A217128-001 | AB | 1 | ea1830bbd6c7… |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A217128-001 | AB | 1 | a72a2bbeb626… |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A217128-001 | AB | 1 | 9b2671bbb829… |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A217128-001 | AB | 1 | a67488948f0b… |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A217128-001 | AB | 1 | 3f0d92c62455… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A217128-001 | BX | 1 | a50c72e98297… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Metronidazole | METRONIDAZOLE | Preferred Pharmaceuticals Inc. | 59e53582-244a-4e9d-b18e-75dddc6a5052 | 2026-07-08 | Adverse reactions | 68788-8552-4 68788-8552 68788855204 1969dc9c-4ced-498b-90a6-c027846b7aaf 59e53582-244a-4e9d-b18e-75dddc6a5052 |
| Metronidazole | METRONIDAZOLE | Viona Pharmaceuticals Inc | 93299502-6cb0-48a4-8190-50fef74bdbee | 2024-12-06 | Adverse reactions | 72578-129 |
Adverse event summaries are temporarily unavailable. Other product information remains available.